CRISPR Therapeutics vs Surrozen
CRISPR Therapeutics reported revenue of $4 million in fiscal 2025, about the same as Surrozen's $4 million in fiscal 2025. CRISPR Therapeutics' revenue fell 90.6% in its latest year, and Surrozen's fell 67.4%. CRISPR Therapeutics had an operating margin of -18933.7%, against -1210.6% at Surrozen. Free cash flow was −$346 million at CRISPR Therapeutics and −$30 million at Surrozen.
Side by side
| CRISPR Therapeutics | Surrozen | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $4M | $4M |
| Revenue growth | −90.6% | −67.4% |
| Revenue growth a year, last 5 years | 38.0% | — |
| Gross margin | — | — |
| Operating margin | −18,933.7% | −1,210.6% |
| Net margin | −16,569.8% | −6,960.8% |
| Free cash flow | −$346M | −$30M |
| Free cash flow margin | −9,855.5% | −873.5% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 6.6% | 155.0% |
| Last close | $38.93 | $30.67 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $14.5 million | bought $6.9 million, sold $7.2 million |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CRISPR TherapeuticsSurrozen
Operating margin
Percent of revenue
CRISPR TherapeuticsSurrozen
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CRISPR TherapeuticsSurrozen
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the CRISPR Therapeutics and Surrozen pages.